Context Molecular biomarkers aim to address the established limitations of clinicopathologic
factors to accurately risk stratify patients with prostate cancer (PCa). Questions remain as to …

Simple Summary Several strategies have demonstrated the ability to improve the survival of
patients with both metastatic and nonmetastatic prostate cancer. The old backbone of …

Background The phase III CHAARTED trial established upfront androgen-deprivation
therapy (ADT) plus docetaxel (D) as a standard for metastatic hormone-sensitive prostate …

Purpose: Enzalutamide plus androgen deprivation therapy has previously been shown to
improve clinical outcomes in men with metastatic hormone-sensitive prostate cancer …

The advent of more effective treatment combinations for metastatic hormone-sensitive
prostate cancer (mHSPC) has been built on successes in therapy development for …

Purpose The epithelial-to-mesenchymal transition (EMT) is a fundamental process in tumor
progression that endows cancer cells with migratory and invasive potential. Snail, a zinc …

Simple Summary De novo metastatic hormone-sensitive prostate cancer usually has a
dismal prognosis, which has slightly improved in recent years thanks to the introduction of …

Importance There is a need to identify prognostic biomarkers to guide treatment
intensification in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) …

Metastatic and high-risk localized prostate cancer respond to hormone therapy but
outcomes vary. Following a pre-specified statistical plan, we used Cox models adjusted for …

Standard treatment for metastatic castration-sensitive prostate cancer (mCSPC) was
androgen-deprivation therapy (ADT) for> 7 decades, and this was termed the “all-comers” …